ABCB1 (MDR1) induction defines a common resistance mechanism in paclitaxel- and olaparib-resistant ovarian cancer cells. - Wikidata - awgldk - TriplyDB

ABCB1 (MDR1) induction defines a common resistance mechanism in paclitaxel- and olaparib-resistant ovarian cancer cells.

ABCB1 (MDR1) induction defines a common resistance mechanism in paclitaxel- and olaparib-resistant ovarian cancer cells.

http://www.wikidata.org/entity/Q38758230

about

Decreased expression of microRNA-17 and microRNA-20b promotes breast cancer resistance to taxol therapy by upregulation of NCOA3.Identifying prognostic signature in ovarian cancer using DirGenerank Genetic Dissection of Cancer Development, Therapy Response, and Resistance in Mouse Models of Breast Cancer.Prediction of therapy response in ovarian cancer: Where are we now?Emerging Therapeutics to Overcome Chemoresistance in Epithelial Ovarian Cancer: A Mini-Review.ABCB1 Mediates Cabazitaxel-Docetaxel Cross-Resistance in Advanced Prostate Cancer.Molecular mechanisms of drug resistance in ovarian cancer.Combination of a thioxodihydroquinazolinone with cisplatin eliminates ovarian cancer stem cell-like cells (CSC-LCs) and shows preclinical potential.Efflux inhibition by IWR-1-endo confers sensitivity to doxorubicin effects in osteosarcoma cells.PARP1-Targeted Radiotherapy in Mouse Models of Glioblastoma.Potential signaling pathways as therapeutic targets for overcoming chemoresistance in mucinous ovarian cancer.ΔNp73 regulates the expression of the multidrug-resistance genes ABCB1 and ABCB5 in breast cancer and melanoma cells - a short report.The impact of pharmacokinetic gene profiles across human cancers.Hsa-miRNA-143-3p Reverses Multidrug Resistance of Triple-Negative Breast Cancer by Inhibiting the Expression of Its Target Protein Cytokine-Induced Apoptosis Inhibitor 1

P2860

Q36188321-6571F90C-37A8-4C37-AE84-789D65756454 Q38725310-3FAEB29B-75D7-40AE-8BA8-8B157A1D0E98 Q38798405-C2F3B8EF-BD08-4539-ADA8-2D7EE1021A69 Q39263260-032CA458-D3C8-4F99-B227-F8958C5C8030 Q45070718-FFA6A77A-E138-492E-A892-C2C4E65EC47E Q46495734-2D3F2403-A4CE-468F-869E-AF106284EDD3 Q48274587-665A10BE-E670-47A9-8C20-A5BCCA6C9D3D Q49787658-9109227E-F700-4812-8E0D-08A8FDC0B3D9 Q50142790-716DDF51-EC46-4B6C-994B-7884D7220800 Q52639515-FA8252AA-A787-47AE-BBF6-3854AAB81E89 Q52643559-ED1324BC-2C2E-46BD-B18C-0749B2EF264E Q53476845-A6BE52F8-3080-464B-AC0C-20E0EFD30E46 Q55294975-9EB42753-69D0-4867-913E-8B768C335A12 Q57124843-D10F0961-2B9A-4E38-A453-365D285EF98F

P2860

ABCB1 (MDR1) induction defines a common resistance mechanism in paclitaxel- and olaparib-resistant ovarian cancer cells.

http://www.wikidata.org/entity/Q38758230

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

ABCB1 (MDR1) induction defines ...... esistant ovarian cancer cells.

@en

type

label

ABCB1 (MDR1) induction defines ...... esistant ovarian cancer cells.

@en

prefLabel

ABCB1 (MDR1) induction defines ...... esistant ovarian cancer cells.

@en

P1433

Q38758230-E43E0DD9-FE6B-4CDE-B40F-FAAA2A7675C9

P1476

Q38758230-D779E6E4-B61B-48D9-B4A4-13B614FEC1B8

P2093

Q38758230-06BF8938-0595-4161-92F7-99C100AC4AE7

Q38758230-516F250D-F798-4BA6-A5E8-E6F2C3A31A0E

Q38758230-8C4597F4-C093-46F4-BFDD-CE7690FBA9AA

Q38758230-C79E3008-A713-4149-B9B5-0A00DE52872D

Q38758230-F63D7F06-A5A0-4967-A5A9-A604D58D3440

Q38758230-F63F35A5-F4AC-47B4-B4DD-7F80C2F44BEE

P2860

Q38758230-009E76A1-F6D4-40BC-930D-FA4F827215FB

Q38758230-0A0889D1-C30A-43B1-BE2F-76BE7FC36362

Q38758230-0B047F88-6E46-45F6-BBAE-E3E555FBDA4E

Q38758230-0CC0C23C-21FB-4CA8-B4CF-55884A59A85B

Q38758230-10EFC43E-54EB-43A2-A809-F780E7D968DE

Q38758230-122841C9-5B50-420D-9070-6E520F6C40C8

Q38758230-1402F50A-15A9-4D95-8DAF-15E0E60FAF20

Q38758230-15EC4C10-50F3-4347-8F2E-1C1F3A67CC0F

Q38758230-1A10902B-C592-4E00-B0A4-AD0B93C441F8

Q38758230-1D0BD423-CE4C-46A8-B1BA-E69409AD70DE

P2888

Q38758230-9BA29D52-060E-4B5E-B9C7-E24F045A469E

P304

Q38758230-B8AF97F9-D931-4793-AE90-4D091AA57E41

P31

Q38758230-2CD8A9AD-ED86-4BF5-9FC7-3FC3FB693F5B

P356

Q38758230-66B34034-D194-4B42-8839-E88112B488A7

P407

Q38758230-0DFA6358-FDB0-463A-BD7B-1489B520B53F

P433

Q38758230-9D8AD219-1802-4891-AB81-4E7AF8A6A37B

P478

Q38758230-7995F3B9-86DD-4071-989B-AEE91037219F

P50

Q38758230-3BEAF7EE-F5C2-4E84-93A6-F8FECEABBE1F

Q38758230-91D16D9F-0FBF-469D-94C9-D4F327F7FEDC

P577

Q38758230-D003332D-F5CF-462C-8EED-E1093DAF1275

P6179

Q38758230-6E996799-6B6D-43F6-9330-ACCA2B0574AD

P698

Q38758230-89ECA6DD-9134-4B39-8F88-15EDD5B8D345

P921

Q38758230-086E6A7E-9CDE-4BEE-9E86-A5CB43996560

P932

Q38758230-AE20B3D5-AE43-4AC6-8AAF-28C27FBC777E

P356

P1433

British Journal of Cancer

P1476

ABCB1 (MDR1) induction defines ...... esistant ovarian cancer cells.

@en

P2093

Alison L Scott

http://www.w3.org/2001/XMLSchema#string

Anne-Louise Gannon

http://www.w3.org/2001/XMLSchema#string

Aparajitha Vaidyanathan

http://www.w3.org/2001/XMLSchema#string

Lynne Sawers

http://www.w3.org/2001/XMLSchema#string

Michelle J Ferguson

http://www.w3.org/2001/XMLSchema#string

Susan E Bray

http://www.w3.org/2001/XMLSchema#string

P2860

High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs

Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays

mdr-1 single nucleotide polymorphisms in ovarian cancer tissue: G2677T/A correlates with response to paclitaxel chemotherapy.

Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study.

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

Linear models and empirical bayes methods for assessing differential expression in microarray experiments

Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase

RAD51 up-regulation bypasses BRCA1 function and is a common feature of BRCA1-deficient breast tumors

Resistance to therapy caused by intragenic deletion in BRCA2

Human multidrug-resistant cell lines: increased mdr1 expression can precede gene amplification

P2888

P304

431-441

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/BJC.2016.203

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

115

http://www.w3.org/2001/XMLSchema#string

P50

Probir Chakravarty

P577

2016-07-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1015453074

http://www.w3.org/2001/XMLSchema#string

P698

27415012

http://www.w3.org/2001/XMLSchema#string

P921

P932

4985349

http://www.w3.org/2001/XMLSchema#string